Peptide Critic Community

@atlas01 good idea! I do the same, trial a single or 2, if it makes a difference, I purchase a kit.

Yeah, I almost mentioned that we are not the target audience for most of this stuff. Some of it might be useful down the road, like when there is a cheap once a month NA-931 pill - assuming that works as advertised. There are some treatments for LP(a) in various stages of clinical trials that are twice a year injections that completely shut down your body’s production of LP(a). (alipoprotein a is a cholesterol type protein that causes very high risk of heart disease and stroke and is almost purely genetic.). There are a lot of really interesting RNA and other type drugs coming.

@mrjoshua44 Nice article, thank you! Survo is undoubtedly causing my liver to cut loose with dumping sugar into my bloodstream. Think it's the reason for reflux, nausea, etc, that I don't and never did have on Tirz alone.

@vpeptides Yeah, I noticed that too. But then again here I am ordering years' worth of drugs off Telegram soooo...

Fluffy rat Rebekah had 0.9 mg survo last night and is a wee bit nauseated today. She is sticking to protein drinks today Probably should have kept her at 0.6 mg for another week or 2. Glad I didn't give her 1.2 mg.

For research use only. Not medical advice. Overview Mazdutide (LY3437943) is a dual GLP-1/glucagon agonist similar to survodutide but generally smoother and more tolerable, with a softer glucagon hit and less aggressive appetite suppression. Typical weekly exploration ranges from 2–10 mg, with gradual escalation over 8–12 weeks. It has good synergy with GLP-1/GIP agonists (e.g., tirzepatide) and is commonly used in “Ghetto Reta” stacks due to its cleaner side-effect profile. Weekly Titration Schedule Weeks 1–2: Intro Phase Dose: 2 mg once weekly Purpose: Establish baseline tolerability and assess GI sensitivity. Notes: This is a gentle entry point compared to survodutide’s 0.6 mg start. Weeks 3–4: Light Phase Dose: 4 mg once weekly Produces noticeable appetite reduction but usually without overwhelming gastric slowing. Hold at 2 mg longer if nausea persists. Weeks 5–6: Moderate Phase Dose: 6 mg once weekly This is the working dose for many research subjects. Represents a good balance of efficacy and tolerability. Weeks 7–8: Strong Phase Dose: 8 mg once weekly Strong metabolic effects emerge here. Suitable for subjects who tolerated 6 mg without significant GI burden. Weeks 9–12: Upper-Tier Phase Dose: 10 mg once weekly This is the practical “top end” for most research setups. Only escalate to 10 mg after several weeks of stability at 8 mg. Maintenance Dosing (Week 13+) Standard Maintenance 6–8 mg once weekly Best balance for long-term tolerability. High-End Maintenance 10 mg once weekly Used when the goal is more aggressive metabolic impact or retatrutide-like synergy in stacks. Frequency & Timing Once weekly, same day each week. Delayed GI effects can occur (Day 2–3), especially at ≥6 mg. When stacking with tirzepatide, escalations should be slower than this standalone schedule. Cycle Length Titration requires 8–12 weeks depending on sensitivity. Full research cycles often run 16–48 weeks, typically maintaining 6–10 mg. Common Research Notes Mazdutide is smoother and less nausea-inducing compared to survodutide. Appetite suppression is strong but less abrupt subjects often describe it as “cleaner” or “more natural.” When stacked with tirzepatide, GI effects compound; many researchers cap mazdutide at 4–6 mg in combination protocols.

For research use only. Not medical advice. Overview Survodutide is a dual GLP-1/glucagon receptor agonist typically researched in the 0.6–6 mg weekly range, with gradual escalation over 10–12 weeks. It produces strong appetite suppression and a pronounced metabolic effect due to its glucagon activity — much more aggressive than standard GLP-1 compounds. Slow titration is essential for GI tolerability. Weekly Titration Schedule Weeks 1–2: Intro Phase Dose: 0.6 mg once weekly Purpose: Allow subjects to adapt to GLP-1 + GC stimulation. Notes: Even this low dose can feel strong for GLP-1-naive subjects. Weeks 3–4: Light Phase Dose: 1.2 mg once weekly Appetite suppression increases significantly here. Hold longer at 0.6 mg if nausea or fullness is excessive. Weeks 5–6: Moderate Phase Dose: 1.8 mg once weekly Represents a comfortable mid-range dose for many subjects. Escalate only if prior doses were well tolerated. Weeks 7–8: Strong Phase Dose: 2.4 mg once weekly This dose often produces robust metabolic effects without overwhelming tolerability. Many researchers remain here for multiple weeks before proceeding. Weeks 9–10: High Phase Dose: 3.6 mg once weekly Strong GC-driven thermogenic activity emerges. If subjects struggle at this point, step back to 2.4 mg until stable. Weeks 11–12: Upper-Tier Phase Dose: 4.8 mg once weekly This was near the top end of phase 2 obesity trial dosing. GI and appetite suppression effects intensify; titrate cautiously. Week 13+ Maintenance Two research-validated maintenance ranges: Standard Maintenance 4.8 mg once weekly Provides excellent efficacy with manageable tolerability. Maximum Maintenance 6.0 mg once weekly Represents the high end used in some modeling and extended research runs. Move to 6.0 mg only after 4.8 mg is fully tolerated for several weeks. Frequency & Timing Once weekly at a consistent time. Due to the glucagon component, many subjects experience delayed nausea (Day 2–3). Avoid rushing escalations — Survodutide hits harder per mg than typical GLP-1s. Cycle Length Titration requires 10–12 weeks minimum. Full research cycles typically last 20–48 weeks depending on goals and maintenance dose. Common Research Notes Survodutide is significantly stronger milligram-for-milligram than semaglutide or tirzepatide due to dual receptor activation. GI load increases steeply with each escalation — slow progression improves tolerability. When used in stacks (e.g., tirz + survo “Ghetto Reta”), researchers often cap survo at 0.6–1.5 mg because synergy multiplies the effect.

@Snake-Pepskin i do all 3. #research